visuel-trans-2

A new investment for Wendel Growth

Published : 11.04.2024
#Actualités

In December 2023, Wendel entered into a defi- nitive agreement to acquire a minority interest in Aqemia and invested to support the company’s growth. Aqemia, a French start-up specialized in pharmaceutical research using artificial intelli- gence, has developed a unique technology plat- form (the Launchpad) that combines theoretical physics and generative artificial intelligence. The technology developed by Aqemia creates medi- cation candidates that act on targets responsible for diseases not currently addressed, thereby helping to accelerate drug discovery.

Victoire Laurenty, Principal at Wendel Growth said : “The technology developed by Aqemia from fundamental research and applied to medical research is a worldwide first. We are delighted to be supportingthis team in its mission to find me- dicines faster and more effectively.”